Chun-Liang Lai

Dr. Chun-Liang Lai

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2024 in APL Bioengineering
Verified
Journal Article
Open access
PDF file
CLChun-Liang Lai
Chun-Liang Lai
Riya KarmakarRiya Karmakar
Riya Karmakar
Arvind MukundanArvind Mukundan
Arvind Mukundan
RNRagul Kumar Natarajan
Ragul Kumar Natarajan
SLSong-Cun Lu
Song-Cun Lu
Hsiang-Chen WangHsiang-Chen Wang
Hsiang-Chen Wang
Hyperspectral imaging (HSI) has become an evident transformative apparatus in medical diagnostics. The review aims to appraise the present advancement and challenges in HSI for medical applications. It features a variety of medical applications namely diagnosing diabetic retinopathy, neurodegenerative diseases like Parkinson's and Alzheimer's, which illustrates its effectiveness in early diagnosis, early caries detection in periodontal disease, and dermatology by detecting skin cancer. Regardless of these advances, the challenges exist within every aspect that limits its broader clinical adoption. It has various constraints including difficulties with technology related to the complexity of the HSI system and needing specialist training, which may act as a drawback to its clinical settings. This article pertains to potential challenges expressed in medical applications and probable solutions to overcome these constraints. Successful companies that perform advanced solutions with HSI in terms of medical applications are being emphasized in this study to signal the high level of interest in medical diagnosis for systems to incorporate machine learning ML and artificial intelligence AI to foster precision diagnosis and standardized clinical workflow. This advancement signifies progressive possibilities of HSI in real-time clinical assessments. In conclusion despite HSI has been presented as a significant advanced medical imaging tool, addressing its limitations and probable solutions is for broader clinical adoption.

10 June 2025 in Biosensors
Verified
Journal Article
Open access
PDF file
CLChun-Liang Lai
Chun-Liang Lai
Arvind MukundanArvind Mukundan
Arvind Mukundan
Riya KarmakarRiya Karmakar
Riya Karmakar
RKRoopmeet Kaur
Roopmeet Kaur
KHKuo-Liang Huang
Kuo-Liang Huang
Hsiang-Chen WangHsiang-Chen Wang
Hsiang-Chen Wang
The growing demand for low-cost biosensors has stimulated the study of new technologies and materials like molybdenum disulfide (MoS2). Due to its electroconductive nature and high surface-to-volume ratio, it allows for the ultra-sensitive detection of biomarkers. The crystal structure of MoS2 provides it with a unique micrometer thickness, making it appropriate for biosensing in healthcare, environmental monitoring, and food safety. As compared to traditional materials, MoS2 can work without labels (through field-effect transduction or plasmonic shifts) while maintaining biocompatibility and low-cost fabrication, which fill significant voids in the early diagnosis of diseases. This paper provides an overview of the recent advancements in MoS2-based biosensors, which are primarily focused on the field-effect transistors and surface plasmon resonance techniques and fabrication methods for MoS2-based biosensors like mechanical exfoliation, liquid-phase exfoliation, physical vapor deposition, chemical vapor deposition, and chemical exfoliation, applications in various industries, and their characterization techniques to evaluate the quality and functionality of MoS2 nanosheets in biosensors. While certain challenges remain like improving conductivity and scalability, MoS2-based biosensors serve as a powerful tool for the precise and reliable detection of biomarkers in environmental, food, and healthcare industries.

1 September 2024 in JCO Global Oncology
Verified
Journal Article
Open access
BLBin-Chi Liao
Bin-Chi Liao
NCNai-Jung Chiang
Nai-Jung Chiang
GCGee-Chen Chang
Gee-Chen Chang
WSWu-Chou Su
Wu-Chou Su
YLYung-Hung Luo
Yung-Hung Luo
JYJames Chih-Hsin Yang
James Chih-Hsin Yang
PURPOSE: Tissue-based next-generation sequencing (NGS) analysis is highly recommended for patients with advanced/metastatic non–small cell lung cancer (NSCLC). We investigated a specific patient population with NSCLC that required tissue-based NGS analysis. MATERIALS AND METHODS: We enrolled 500 patients with advanced/metastatic (1) epidermal growth factor receptor ( EGFR ) mutations or anaplastic large-cell lymphoma kinase ( ALK ) rearrangement–positive NSCLC who had failed at minimum one line of tyrosine kinase inhibitor (TKI) therapy, (2) EGFR-/ALK -negative nonsquamous, and (3) non- or light-smoker patients with squamous NSCLC who were treatment-naïve or had failed at maximum two lines of systemic treatment. These patients were divided into five cohorts. Comprehensive tissue-based NGS testing (ACTOnco+) was conducted. RESULTS: Cohort 1: EGFR TKI-pretreated EGFR -mutated population (50.0%, n = 250), cohort 2: ALK inhibitor-pretreated ALK -positive population (1.6%, n = 8), cohort 3: treatment-naïve EGFR-/ALK -negative population (28.2%, n = 141), cohort 4: pretreated EGFR-/ALK -negative population (16.8%, n = 84), and cohort 5: squamous cell carcinoma (3.4%, n = 17). In cohort 1, 11.2% (28/250) of the patients had MET amplification, 32.4% (81/250) had been treated with osimertinib, and EGFR C797S was detected in 6.2% (5/81) of these patients. In cohort 2, resistance ALK mutation was detected in 37.5% (3/8) of the patients. In cohorts 3 and 4, targetable genetic alterations, including EGFR mutation (13.3%), ERBB2 mutation (9.3%), MET exon 14 skipping (5.3%), KRAS G12C mutation (4.4%), ROS1 fusion (2.7%), RET fusion (1.8%), and BRAF V600E mutation (1.3%), were detected. In cohort 5, MET exon 14 skipping was detected in 29.4% (5/17) of the patients. CONCLUSION: This multicenter registration study investigated tissue-based NGS for a specific patient population with NSCLC in Taiwan.

28 October 2025 in Biosensors
Verified
Journal Article
Open access
PDF file
CLChun-Liang Lai
Chun-Liang Lai
KLKun-Hua Lee
Kun-Hua Lee
Hong-Thai NguyenHong-Thai Nguyen
Hong-Thai Nguyen
Arvind MukundanArvind Mukundan
Arvind Mukundan
Riya KarmakarRiya Karmakar
Riya Karmakar
Hsiang-Chen WangHsiang-Chen Wang
Hsiang-Chen Wang
Malignant pleural effusion, commonly referred to as MPE, is a prevalent complication associated with individuals diagnosed with neoplastic disorders. The data acquired by pleural fluid cytology is beneficial for diagnostic objectives. Consequently, the initial step in the diagnostic procedure for lung cancer is the analysis of pleural effusion fluid. This research aims to provide a cutting-edge model for analyzing PE cytology images. This model utilizes a computer-aided diagnosis (CAD) system that integrates hyperspectral imaging (HSI) technology for the classification of spectral variations. Giemsa, which is one of the most popular microscopic stains, is employed to stain the samples, after which a sensitive CCD mounted on a microscope captures the images. Subsequently, the HSI model is tasked with obtaining the image spectra. Principal Component Analysis (PCA) constitutes the concluding phase in the classification procedure of various cell types. We expect that the suggested technique will enable medical professionals to stage lung cancer more rapidly. In the future, we aspire to develop an extensive data system that utilizes deep learning techniques to facilitate the automatic classification of cells, thereby ensuring the most precise diagnosis. Furthermore, enhancing accuracy and minimizing data dimensions are important priorities to accelerate diagnostics, conserve resources, and reduce computing time.